2023 World Conference on Lung Cancer (Posters)-P1.25. Prevalence of EGFR Mutations in Patients with Resected Stage I-III NSCLC: Results of the Asian Cohort of EARLY-EGFR

P1.25. Prevalence of EGFR Mutations in Patients with Resected Stage I-III NSCLC: Results of the Asian Cohort of EARLY-EGFR - PDF(Abstract)

Back to course

Pdf Summary

This abstract reports the findings of a study called EARLY-EGFR, which investigated the prevalence of EGFR mutations in patients with early-stage non-small cell lung cancer (NSCLC) in the Asian population. The study enrolled a total of 505 patients with surgically-resected stage I-III NSCLC from five countries in Asia. The primary endpoint was the prevalence of EGFR mutations, and secondary endpoints included EGFR mutation subtypes, clinicopathological characteristics, and treatment patterns. <br /><br />The results showed that the prevalence of EGFR mutations across all stages of NSCLC was 53.0%. Exon-19 deletions accounted for the majority of the mutations (52.6%), followed by L858R (37.6%). EGFR mutation-positive tumors were PD-L1 positive in 42.9% of cases. A higher proportion of EGFR mutations were found in stage I disease, females, and non-smokers. <br /><br />Most patients (73.3%) underwent only surgical resection, while 27.1% received systemic therapy, primarily platinum-based chemotherapy, in neoadjuvant and adjuvant settings. Age over 60 and female gender were associated with higher odds of EGFR mutations, while stage III disease had lower odds. <br /><br />The authors concluded that approximately 49% of stage IB-IIIA NSCLC patients in the Asian cohort had EGFR mutations, making them eligible for adjuvant osimertinib treatment. They also highlighted the need for more guideline-conform treatments, as a significant proportion of stage II/III and stage IB patients received surgery only without neoadjuvant or adjuvant therapy. The authors recommended upfront EGFR testing in NSCLC from stage IB onwards and multidisciplinary management to optimize treatment sequencing. These findings call for attention to the importance of EGFR testing and personalized treatment approaches for early-stage NSCLC patients in Asia.

Asset Subtitle

Tu Dao

Meta Tag

Speaker Tu Dao

Topic Early-Stage NSCLC: Changing Paradigms & Outcomes

Keywords

EGFR mutations

non-small cell lung cancer

Asian population

surgically-resected

stage I-III

exon-19 deletions

L858R

PD-L1 positive

platinum-based chemotherapy

adjuvant osimertinib treatment